Subepithelial Tumors of the Upper Gastrointestinal TractDopplerSELNCT05983406
Role of Doppler Endoscopic Probe in the Diagnosis of Subepithelial Gastrointestinal Lesions.
A study testing Doppler investigation in people with Subepithelial Tumors of the Upper Gastrointestinal Tract, run by Francisco Baldaque-Silva at 1 site in Sweden.
Trial summary
RESEARCH PLAN I-TITLE Role of Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions. II-BACKGROUND Subepithelial lesions (SEL) are commonly encountered during routine endoscopies with an estimated prevalence of 3.5%. Most of the SELs are detected during upper gastrointestinal endoscopy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Subepithelial Tumors of the Upper Gastrointestinal Tract
- What is being tested?
- Doppler investigation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSweden
- Study dates
- 1 Aug 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Presence of subepithelial lesion on the GI tract.
Who cannot join
- Anticoagulation therapy that cannot be discontinued
- Liver cirrhosis with coagulopathy or varices
- Malignancy
Trial locations and contacts
1 site in 1 country.
Sweden1 site, 1 recruiting
- Recruiting
Karolinska University Hospital & Karolinska Institute
Stockholm, 11346
Karolinska University Hospital & K Institute
About this study
RESEARCH PLAN I-TITLE Role of Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.
II-BACKGROUND Subepithelial lesions (SEL) are commonly encountered during routine endoscopies with an estimated prevalence of 3.5%. Most of the SELs are detected during upper gastrointestinal endoscopy. Subsequently, endoscopic ultrasound (EUS) is performed to better characterize the lesion and to rule out the presence of a vascular lesion before tissue sampling due to the high risk of severe bleeding with tissue acquisition in vascular injury. However, EUS can rarely establish a definitive diagnosis per se with limited accuracy.
Read more
In large lesions, it is possible to use cytology or histology needles via the EUS instrument to collect cells/tissue within the lesion. It can lead to accurate diagnosis and consistent management. However, EUS-guided tissue sampling can be technically challenging, with poor yield for small or mobile SELs. In addition, EUS is an expensive technique, high operator dependency and performed only in tertiary centers. It creates a time gap between endoscopic detection and the EUS examination and increases costs. That delay in diagnosis is a source of anxiety for the patient and for the caregivers.
Several methods were proposed to increase the diagnostic yield of tissue acquisition techniques, such as "bite-on-bite" biopsies which showed a limited diagnostic yield. Alternatively, the "unroofing" technique has also been advocated for histological diagnosis. In unroofing, a loop is used to remove the normal epithelium covering the subepithelial lesions and after epithelial removal, a biopsy forceps or loop is used to sample subepithelial lesions. Other techniques include endoscopic resection by snare or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.
There is a need for a method that enables rapid diagnosis in the same session as endoscopic detection of SEL regardless of their size. That method should ideally enable histological diagnosis with low risks of complications and should not require high technical expertise and should not be highly dependent on the operator. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as endoscopic detection.
Doppler endoscopic probe (DEP) is a Doppler endoscopic probe specially developed for the GI system, which enables blood flow detection during endoscopy.
DEP is CE and FDA approved and can be used through the working channel of the endoscope. Unlike standard EUS, which requires advanced endoscopic training, DEP is much easier to use. It allows the characterization of lesions as non-vascular, venous or arterial. Recent studies have demonstrated the safety and efficacy of DEP in vascular characterization in the gastrointestinal tract.
III PURPOSE
Primary objective:
- Proof of concept evaluation of the role of DEP in the characterization of GI SEL as non-vascular or vascular (arterial or venous)
- Relationship between findings on DEP versus findings on EUS (considered the gold standard) regarding SEL characterization as non-vascular or vascular (arterial or venous).
Secondary purposes:
- Accuracy in removing the histological characterization of subepithelial GI lesions.
- Complications in connection with tissue acquisition
- Inter-observer agreement of DEP and EUS results. IV METHODS This is a pilot projective feasibility study that will be run by Karolinska University Hospital in Stockholm Patients with subepithelial GI lesions were referred for EUS evaluation. The study will include 30 patients.
A conventional gastroscopy will be performed. After identification of the lesion, DEP is performed. The DEP probe is lubricated and deployed through the working channel of the endoscope. The probe will contact the mucosa slightly, covering the SEL. Then evaluate the lesion in 2 different angels. The results will be characterized and recorded qualitatively: no flow / arterial flow / venous flow and in terms of intensity: soft, medium or high.
After DEP, evaluation EUS will be performed by another endoscopist who will be tied to the DEP results. EUS will be considered the gold standard.
After both assessments, the lesion is characterized as no vessel / arterial / venous and as soft / medium / high flow intensity.
EUS will be followed by removal of SEL in patients where EUS excludes the presence of high vessel disease. "Unroofing" will be performed using a conventional endoscopic loop, through the working channel of the endoscope. After the surface of the lesion is disturbed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by the pathologist.
Read the detailed description
RESEARCH PLAN
I-TITLE Role of doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.
II-BACKGROUND
Subepithelial lesions (SELs) are commonly encountered on routine endoscopies with estimated prevalence of 3.5% (PMID: 24238309). Most small SELs are asymptomatic and benign, but their pathological diagnosis may be challenging, and sometimes impossible with conventional technology.
Most of SELs are detected during upper gastrointestinal endoscopy. Afterwards, endoscopic ultrasound (EUS) is usually performed in order to better characterize the lesion and to exclude the presence of a vascular lesion. EUS enables evaluation of the size, structure and location of the lesion within the GI wall (submucosa/muscularis mucosa/ submucosa/muscularis propria), but can seldom stablish a definitive diagnosis per se. EUS provides valuable information regarding the layer of origin and can suggest a diagnosis, but it has been shown to have limited accuracy. (PMID: 12190103).
In lesions larger than 2cm, it is possible to use dedicated cytologi (FNA) or histology (FNB) needles thought the EUS instrument in order to collect cells/tissue from within the lesion. That may lead to proper diagnosis and consequent management. However, EUS-guided tissue sampling can be technically challenging, with poor yields for small or mobile SELs (20306384). Additionally, EUS is an expensive technique, highly operator dependent and usually only performed in tertiary centers. That creates a time gap between the endoscopic detection and the EUS investigation, and increases the costs. That delay in the diagnosis is a source of anxiety for the patient and for health care providers alike.
In cases with small or mobile SEL, in which a definitive diagnosis cannot be stablished with EUS plus FNA/FNB, surveillance is recommended. But the later, is associated with high costs and high burden for the health care system.
Several methods were advocated to increase the diagnostic yield of tissue acquisition techniques such as "bite- on-bite" forceps biopsy that showed a limited diagnostic yield (PMID: 12518134), with one prospective study showing a diagnostic yield of only 17% compared with 87% with endoscopic resection (PMID: 16813799). Alternatively, unroofing technique has also been advocated in this context. With unroofing a snare is used to remove the normal epithelium that is covering the subepithelial lesion, and after epithelial removal a biopsy forceps is used to sample the subepithelial lesion. Other techniques include endoscopic resection by snaring or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.
Although endoscopic resection may have the advantage of providing both a complete pathological diagnosis as well as treatment for the tumor in selected patients, it is questionable whether endoscopic resection of the entire lesion is needed for diagnostic purposes, because of the associated long procedure time and potentially serious complications, such as bleeding and perforation.
EUS is usually performed before biopsy sampling, snaring or endoscopic resection in order to exclude the presence of a highly vascular SEL, due to the high risk of severe bleeding in case of tissue acquisition in a vascular lesion.
There is a need for a method that would enable rapid diagnosis in the same session as endoscopic detection of SELs irrespective of their size. That method should ideally enable histological diagnosis with low risks of complications and should not demand high technical expertise and should not be highly operator dependent. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as the endoscopic diagnosis.
Doppler endoscopic probe (DEP) is a 2-mm diameter, single-use, Doppler endoscopic probe (Vascular Technology Inc, Nashua, NH) specifically developed for GI tract, that enables blood flow detection during endoscopy. As lesions are unlikely to bleed substantially without a major supply of blood flow, the applicability of endoscopic DEP resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract.
DEP is CE and FDA approved and may be used through the working channel of the endoscope. The DEP system is a 20-MHz, pulsed-wave Doppler ultrasound unit with 3 preset scanning depths: from the surface to 1.5, 4, and 7 mm. It has an audible Doppler output signal but does not have a visual monitor display. The unit is portable and battery-powered. Unlike standard EUS, which requires advanced endoscopic training, DEP is much more straightforward to use (15557966). The applicability of endoscopic Doppler US resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract. A positive DEP signal has been defined as a repetitive and similar visual spiking waveform (or audible signal) of at least 3 consecutive cycle duration (indicating pulsatile blood flow and minimizing the chance of a false-positive signal) (PMID: 10968843).
Recent studies had demonstrated the safety and efficacy of DEP in the vascular characterization of gastrointestinal peptic ulcers (26318834, 28167214).
III- AIMS
Primary aims:
- Proof-of-concept evaluation of the role of DEP in the characterization of GI SEL as highly vascular or non-highly vascular.
- Correlation between findings on DEP versus finding on EUS (considered the gold standard) in terms of SEL characterization as highly vascular or non-highly vascular.
Secondary aims:
- Accuracy of unroofing in the histological characterization of subepitelial GI lesions.
- Complications associated with tissue acquisition through unroofing technique such as bleeding or perforation
- Inter-observer agreement of the DEP findings.
IV- METHODS
STUDY DESIGN
This is a pilot prospective feasibility study that will be run by Karolinska University Hospital in Stockholm
STUDY POPULATION Patients with subepithelial GI lesions referred for EUS evaluation. The study will include 20 patients.
Inclusion criteria
- Presence of subepithelial lesion on the GI tract.
Exclusion criteria
- Anticoagulation therapy that cannot be discontinued
- Liver cirrhosis with coagulopathy or varices
- Malignancy
All patients will receive a detailed explanation regarding the procedure, its risks, benefits, and alternatives, and provided written informed consent before inclusion (Appendix 1).
Participants clinical, demographic, and procedural information will be obtained and recorded at enrollment (Appendix 2).
Patients under antiplatelet or anticoagulant drugs will be handled according to published guidelines.
OUTCOME PARAMETERS PRIMARY OUTCOME PARAMETERS DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud.
Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.
SECONDARY OUTCOME PARAMETERS Adverse events are defined as any complication in which DEP, EUS, unroofing or related procedures are a contributing factor and include bleeding and perforation.
Perforation is defined as a full thickness breach in the GI wall with or without symptoms.
Intraprocedural bleeding is considered significant and a complication when:
- blood transfusion is needed
- premature termination of endoscopic occurs
Delayed bleeding is defined as clinical evidence of bleeding manifested by melena or hematochezia from up to 14 days after the procedure that demanded presentation to the emergency department, hospital admission or medical intervention.
Adverse events are classified as:
- acute (during procedure)
- early (<48 h)
- late (>48 h).
In terms of severity they are characterized as:
- mild (unplanned medical assistance, hospital admission, hospitalization <3 days, hemoglobin drop <3 g, no transfusion)
- moderate (4-10 days hospitalization, <4 units blood transfusion, repeat endoscopic intervention, radiological intervention)
- severe (hospitalization >10 days, intensive care unit (ICU) admission, need for surgery, >4 units blood transfusion) or fatal (death attributable to procedure) [7, 8].
ENDOSCOPIC PROTOCOL
A conventional gastroscopy will be performed. After identification of the lesion, DEP will be performed. The DEP probe will be lubricated and deployed through the working channel of the endoscope. The probe will contact slightly the mucosa covering the SEL. Then will evaluate the lesion in 2 different angels (one at the top and one at the base of the lesion). First, the superficial Doppler depth setting (< 1.5 mm) will be used, followed by the middle setting (< 4 mm). Assessment will be recorded and endoscopist diagnosis (arterial flow/venous flow, soft/medium/loud intensity) will be registered. All DEP will be performed by the same endoscopist (MO). Findings will be characterized and registered qualitatively: no flow/arterial flow/venous flow and in terms of intensity: soft, medium, or loud.
After DEP, evaluation EUS will be performed by another endoscopists (FBS) that will be blinded to the DEP findings. EUS will be considered the gold standard.
After both assessments the lesion will be characterized as no vascular/low vascular/highly vascular flow.
EUS will be followed by unroofing of the SEL in patients in which EUS excluded the presence of a highly vascular lesion. Unroofing will be performed using a conventional endoscopic snare, through the working channel of the endoscope. After the surface of the lesion is unroofed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by pathologist.
All data will be registered. All procedures will be recorded in video and audio (DEP).
POST PROCEDURE PROTOCOL
Before Discharge After unroofing, patients will be closely monitored for 2-4 hours under continuous monitoring and then discharged if no complications detected.
After Discharge At week 8 after discharge, patients will have a hospital visit for assessment of complications and control endoscopy.
V-SIGNIFICANCE With this study it will be possible to evaluate the strategy of DEP and unroofing in the assessment of GI SEL. In case of positive results: good accuracy in the diagnosis/exclusion of vascular lesions with DEP and good histological yield with unroofing, this strategy may be further validated and might change the paradigm of management of GI SEL.
- Being tested
- Doppler investigation
- Keywords
- Doppler, EUS, SEL
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Doppler investigationDevice
Doppler investigation
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions Receives: Device: Doppler investigation |
What is being measured
The primary outcome is the main question the study is designed to answer.
DEP accuracy
DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud. Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.
Measured: From enrollment to the end of study at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2023
- Study start1 Aug 2023
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Subepithelial Tumors of the Upper Gastrointestinal TractStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Francisco Baldaque-Silva
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Francisco Baldaque-Silva, Karolinska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05983406
- Sponsor's protocol ID
- KarolinskaUH 2019-05404
- Other IDs
- 2019-05404, 2019
- Acronym
- DopplerSEL
- Status last verified
- Aug 2023
- First submitted
- 1 Aug 2023
- Last updated
- 9 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hunt GC, Smith PP, Faigel DO. Yield of tissue sampling for submucosal lesions evaluated by EUS. Gastrointest Endosc. 2003 Jan;57(1):68-72. doi: 10.1067/mge.2003.34.
PubMed 12518134Philipper M, Hollerbach S, Gabbert HE, Heikaus S, Bocking A, Pomjanski N, Neuhaus H, Frieling T, Schumacher B. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. Endoscopy. 2010 Apr;42(4):300-5. doi: 10.1055/s-0029-1244006. Epub 2010 Mar 19.
PubMed 20306384Rosch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R, Ulm K; German EUS Club. Endoscopic ultrasonography. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand J Gastroenterol. 2002 Jul;37(7):856-62.
PubMed 12190103Binmoeller KF, Shah JN, Bhat YM, Kane SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm loop for the diagnosis and therapy of small subepithelial tumors (with video). Gastrointest Endosc. 2014 May;79(5):750-5. doi: 10.1016/j.gie.2013.09.028. Epub 2013 Nov 12.
PubMed 24238309
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Doppler Endoscopic Probe in the Diagnosis of Subepithelial Gastrointestinal Lesions.
- ClinicalTrials.gov ID
- NCT05983406
- Acronym / sponsor ID
- DopplerSEL / KarolinskaUH 2019-05404
- Keywords
- Doppler, EUS, SEL
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Francisco Baldaque-SilvaUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 9 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RESEARCH PLAN I-TITLE Role of Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.
II-BACKGROUND Subepithelial lesions (SEL) are commonly encountered during routine endoscopies with an estimated prevalence of 3.5%. Most of the SELs are detected during upper gastrointestinal endoscopy. Subsequently, endoscopic ultrasound (EUS) is performed to better characterize the lesion and to rule out the presence of a vascular lesion before tissue sampling due to the high risk of severe bleeding with tissue acquisition in vascular injury. However, EUS can rarely establish a definitive diagnosis per se with limited accuracy.
In large lesions, it is possible to use cytology or histology needles via the EUS instrument to collect cells/tissue within the lesion. It can lead to accurate diagnosis and consistent management. However, EUS-guided tissue sampling can be technically challenging, with poor yield for small or mobile SELs. In addition, EUS is an expensive technique, high operator dependency and performed only in tertiary centers. It creates a time gap between endoscopic detection and the EUS examination and increases costs. That delay in diagnosis is a source of anxiety for the patient and for the caregivers.
Several methods were proposed to increase the diagnostic yield of tissue acquisition techniques, such as "bite-on-bite" biopsies which showed a limited diagnostic yield. Alternatively, the "unroofing" technique has also been advocated for histological diagnosis. In unroofing, a loop is used to remove the normal epithelium covering the subepithelial lesions and after epithelial removal, a biopsy forceps or loop is used to sample subepithelial lesions. Other techniques include endoscopic resection by snare or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.
There is a need for a method that enables rapid diagnosis in the same session as endoscopic detection of SEL regardless of their size. That method should ideally enable histological diagnosis with low risks of complications and should not require high technical expertise and should not be highly dependent on the operator. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as endoscopic detection.
Doppler endoscopic probe (DEP) is a Doppler endoscopic probe specially developed for the GI system, which enables blood flow detection during endoscopy.
DEP is CE and FDA approved and can be used through the working channel of the endoscope. Unlike standard EUS, which requires advanced endoscopic training, DEP is much easier to use. It allows the characterization of lesions as non-vascular, venous or arterial. Recent studies have demonstrated the safety and efficacy of DEP in vascular characterization in the gastrointestinal tract.
III PURPOSE
Primary objective:
- Proof of concept evaluation of the role of DEP in the characterization of GI SEL as non-vascular or vascular (arterial or venous)
- Relationship between findings on DEP versus findings on EUS (considered the gold standard) regarding SEL characterization as non-vascular or vascular (arterial or venous).
Secondary purposes:
- Accuracy in removing the histological characterization of subepithelial GI lesions.
- Complications in connection with tissue acquisition
- Inter-observer agreement of DEP and EUS results. IV METHODS This is a pilot projective feasibility study that will be run by Karolinska University Hospital in Stockholm Patients with subepithelial GI lesions were referred for EUS evaluation. The study will include 30 patients.
A conventional gastroscopy will be performed. After identification of the lesion, DEP is performed. The DEP probe is lubricated and deployed through the working channel of the endoscope. The probe will contact the mucosa slightly, covering the SEL. Then evaluate the lesion in 2 different angels. The results will be characterized and recorded qualitatively: no flow / arterial flow / venous flow and in terms of intensity: soft, medium or high.
After DEP, evaluation EUS will be performed by another endoscopist who will be tied to the DEP results. EUS will be considered the gold standard.
After both assessments, the lesion is characterized as no vessel / arterial / venous and as soft / medium / high flow intensity.
EUS will be followed by removal of SEL in patients where EUS excludes the presence of high vessel disease. "Unroofing" will be performed using a conventional endoscopic loop, through the working channel of the endoscope. After the surface of the lesion is disturbed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by the pathologist.
Detailed description
RESEARCH PLAN
I-TITLE Role of doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.
II-BACKGROUND
Subepithelial lesions (SELs) are commonly encountered on routine endoscopies with estimated prevalence of 3.5% (PMID: 24238309). Most small SELs are asymptomatic and benign, but their pathological diagnosis may be challenging, and sometimes impossible with conventional technology.
Most of SELs are detected during upper gastrointestinal endoscopy. Afterwards, endoscopic ultrasound (EUS) is usually performed in order to better characterize the lesion and to exclude the presence of a vascular lesion. EUS enables evaluation of the size, structure and location of the lesion within the GI wall (submucosa/muscularis mucosa/ submucosa/muscularis propria), but can seldom stablish a definitive diagnosis per se. EUS provides valuable information regarding the layer of origin and can suggest a diagnosis, but it has been shown to have limited accuracy. (PMID: 12190103).
In lesions larger than 2cm, it is possible to use dedicated cytologi (FNA) or histology (FNB) needles thought the EUS instrument in order to collect cells/tissue from within the lesion. That may lead to proper diagnosis and consequent management. However, EUS-guided tissue sampling can be technically challenging, with poor yields for small or mobile SELs (20306384). Additionally, EUS is an expensive technique, highly operator dependent and usually only performed in tertiary centers. That creates a time gap between the endoscopic detection and the EUS investigation, and increases the costs. That delay in the diagnosis is a source of anxiety for the patient and for health care providers alike.
In cases with small or mobile SEL, in which a definitive diagnosis cannot be stablished with EUS plus FNA/FNB, surveillance is recommended. But the later, is associated with high costs and high burden for the health care system.
Several methods were advocated to increase the diagnostic yield of tissue acquisition techniques such as "bite- on-bite" forceps biopsy that showed a limited diagnostic yield (PMID: 12518134), with one prospective study showing a diagnostic yield of only 17% compared with 87% with endoscopic resection (PMID: 16813799). Alternatively, unroofing technique has also been advocated in this context. With unroofing a snare is used to remove the normal epithelium that is covering the subepithelial lesion, and after epithelial removal a biopsy forceps is used to sample the subepithelial lesion. Other techniques include endoscopic resection by snaring or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.
Although endoscopic resection may have the advantage of providing both a complete pathological diagnosis as well as treatment for the tumor in selected patients, it is questionable whether endoscopic resection of the entire lesion is needed for diagnostic purposes, because of the associated long procedure time and potentially serious complications, such as bleeding and perforation.
EUS is usually performed before biopsy sampling, snaring or endoscopic resection in order to exclude the presence of a highly vascular SEL, due to the high risk of severe bleeding in case of tissue acquisition in a vascular lesion.
There is a need for a method that would enable rapid diagnosis in the same session as endoscopic detection of SELs irrespective of their size. That method should ideally enable histological diagnosis with low risks of complications and should not demand high technical expertise and should not be highly operator dependent. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as the endoscopic diagnosis.
Doppler endoscopic probe (DEP) is a 2-mm diameter, single-use, Doppler endoscopic probe (Vascular Technology Inc, Nashua, NH) specifically developed for GI tract, that enables blood flow detection during endoscopy. As lesions are unlikely to bleed substantially without a major supply of blood flow, the applicability of endoscopic DEP resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract.
DEP is CE and FDA approved and may be used through the working channel of the endoscope. The DEP system is a 20-MHz, pulsed-wave Doppler ultrasound unit with 3 preset scanning depths: from the surface to 1.5, 4, and 7 mm. It has an audible Doppler output signal but does not have a visual monitor display. The unit is portable and battery-powered. Unlike standard EUS, which requires advanced endoscopic training, DEP is much more straightforward to use (15557966). The applicability of endoscopic Doppler US resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract. A positive DEP signal has been defined as a repetitive and similar visual spiking waveform (or audible signal) of at least 3 consecutive cycle duration (indicating pulsatile blood flow and minimizing the chance of a false-positive signal) (PMID: 10968843).
Recent studies had demonstrated the safety and efficacy of DEP in the vascular characterization of gastrointestinal peptic ulcers (26318834, 28167214).
III- AIMS
Primary aims:
- Proof-of-concept evaluation of the role of DEP in the characterization of GI SEL as highly vascular or non-highly vascular.
- Correlation between findings on DEP versus finding on EUS (considered the gold standard) in terms of SEL characterization as highly vascular or non-highly vascular.
Secondary aims:
- Accuracy of unroofing in the histological characterization of subepitelial GI lesions.
- Complications associated with tissue acquisition through unroofing technique such as bleeding or perforation
- Inter-observer agreement of the DEP findings.
IV- METHODS
STUDY DESIGN
This is a pilot prospective feasibility study that will be run by Karolinska University Hospital in Stockholm
STUDY POPULATION Patients with subepithelial GI lesions referred for EUS evaluation. The study will include 20 patients.
Inclusion criteria
- Presence of subepithelial lesion on the GI tract.
Exclusion criteria
- Anticoagulation therapy that cannot be discontinued
- Liver cirrhosis with coagulopathy or varices
- Malignancy
All patients will receive a detailed explanation regarding the procedure, its risks, benefits, and alternatives, and provided written informed consent before inclusion (Appendix 1).
Participants clinical, demographic, and procedural information will be obtained and recorded at enrollment (Appendix 2).
Patients under antiplatelet or anticoagulant drugs will be handled according to published guidelines.
OUTCOME PARAMETERS PRIMARY OUTCOME PARAMETERS DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud.
Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.
SECONDARY OUTCOME PARAMETERS Adverse events are defined as any complication in which DEP, EUS, unroofing or related procedures are a contributing factor and include bleeding and perforation.
Perforation is defined as a full thickness breach in the GI wall with or without symptoms.
Intraprocedural bleeding is considered significant and a complication when:
- blood transfusion is needed
- premature termination of endoscopic occurs
Delayed bleeding is defined as clinical evidence of bleeding manifested by melena or hematochezia from up to 14 days after the procedure that demanded presentation to the emergency department, hospital admission or medical intervention.
Adverse events are classified as:
- acute (during procedure)
- early (<48 h)
- late (>48 h).
In terms of severity they are characterized as:
- mild (unplanned medical assistance, hospital admission, hospitalization <3 days, hemoglobin drop <3 g, no transfusion)
- moderate (4-10 days hospitalization, <4 units blood transfusion, repeat endoscopic intervention, radiological intervention)
- severe (hospitalization >10 days, intensive care unit (ICU) admission, need for surgery, >4 units blood transfusion) or fatal (death attributable to procedure) [7, 8].
ENDOSCOPIC PROTOCOL
A conventional gastroscopy will be performed. After identification of the lesion, DEP will be performed. The DEP probe will be lubricated and deployed through the working channel of the endoscope. The probe will contact slightly the mucosa covering the SEL. Then will evaluate the lesion in 2 different angels (one at the top and one at the base of the lesion). First, the superficial Doppler depth setting (< 1.5 mm) will be used, followed by the middle setting (< 4 mm). Assessment will be recorded and endoscopist diagnosis (arterial flow/venous flow, soft/medium/loud intensity) will be registered. All DEP will be performed by the same endoscopist (MO). Findings will be characterized and registered qualitatively: no flow/arterial flow/venous flow and in terms of intensity: soft, medium, or loud.
After DEP, evaluation EUS will be performed by another endoscopists (FBS) that will be blinded to the DEP findings. EUS will be considered the gold standard.
After both assessments the lesion will be characterized as no vascular/low vascular/highly vascular flow.
EUS will be followed by unroofing of the SEL in patients in which EUS excluded the presence of a highly vascular lesion. Unroofing will be performed using a conventional endoscopic snare, through the working channel of the endoscope. After the surface of the lesion is unroofed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by pathologist.
All data will be registered. All procedures will be recorded in video and audio (DEP).
POST PROCEDURE PROTOCOL
Before Discharge After unroofing, patients will be closely monitored for 2-4 hours under continuous monitoring and then discharged if no complications detected.
After Discharge At week 8 after discharge, patients will have a hospital visit for assessment of complications and control endoscopy.
V-SIGNIFICANCE With this study it will be possible to evaluate the strategy of DEP and unroofing in the assessment of GI SEL. In case of positive results: good accuracy in the diagnosis/exclusion of vascular lesions with DEP and good histological yield with unroofing, this strategy may be further validated and might change the paradigm of management of GI SEL.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Device: Doppler investigationDoppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Presence of subepithelial lesion on the GI tract.
Key exclusion criteria (3 listed)
- Anticoagulation therapy that cannot be discontinued
- Liver cirrhosis with coagulopathy or varices
- Malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Doppler investigationDoppler investigation | Device | Intervention |
Primary outcome
DEP accuracy
Time frame: From enrollment to the end of study at 8 weeks
DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud. Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2023.
- Background: PubMed 12518134Hunt GC, Smith PP, Faigel DO. Yield of tissue sampling for submucosal lesions evaluated by EUS. Gastrointest Endosc. 2003 Jan;57(1):68-72. doi: 10.1067/mge.2003.34.
- Background: PubMed 20306384Philipper M, Hollerbach S, Gabbert HE, Heikaus S, Bocking A, Pomjanski N, Neuhaus H, Frieling T, Schumacher B. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. Endoscopy. 2010 Apr;42(4):300-5. doi: 10.1055/s-0029-1244006. Epub 2010 Mar 19.
- Background: PubMed 12190103Rosch T, Kapfer B, Will U, Baronius W, Strobel M, Lorenz R, Ulm K; German EUS Club. Endoscopic ultrasonography. Accuracy of endoscopic ultrasonography in upper gastrointestinal submucosal lesions: a prospective multicenter study. Scand J Gastroenterol. 2002 Jul;37(7):856-62.
- Background: PubMed 24238309Binmoeller KF, Shah JN, Bhat YM, Kane SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm loop for the diagnosis and therapy of small subepithelial tumors (with video). Gastrointest Endosc. 2014 May;79(5):750-5. doi: 10.1016/j.gie.2013.09.028. Epub 2013 Nov 12.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Doppler investigation in people with Subepithelial Tumors of the Upper Gastrointestinal Tract, run by Francisco Baldaque-Silva at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francisco Baldaque-Silva, MD PhD (+46704997219, fbaldaquesilva@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DEP accuracy (time frame: From enrollment to the end of study at 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05983406, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2023.